By Fineline Cube 
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs alveltamig (ZG006), nilvanstomig (ZG005), and ZGGS15 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlighted the promising efficacy and safety profiles of these drugs across multiple cancer types.
Alveltamig (ZG006) Clinical Results
Alveltamig, a trispecific antibody targeting two epitopes of DLL3 and CD3, showed impressive results in the Phase II dosage optimization study for refractory advanced small cell lung cancer (SCLC). Objective response rates (ORRs) were 62.5% (10mg) and 58.3% (30mg), with disease control rates (DCRs) of 70.8% (10mg) and 66.7% (30mg). Additional studies (ZG006-001 and ZG006-003) further confirmed its anti-tumor activity and tolerability.
Nilvanstomig (ZG005) Clinical Results
Nilvanstomig, an anti PD-1/TIGIT bispecific antibody, demonstrated significant efficacy in cervical cancer patients. In the ZG005-001 study, the 20mg/kg group showed a confirmed ORR of 40.9% and DCR of 68.2%. Combination therapies in ZG005-003 and ZG005-004 studies also yielded high ORRs and DCRs, highlighting its potential in advanced cervical and neuroendocrine cancers.
ZGGS15 Clinical Results
ZGGS15, a bispecific antibody targeting LAG-3 and TIGIT, showed a disease control rate (DCR) of 35.3% in the ZGGS15-001 study, with 62.5% of lung adenocarcinoma patients achieving stable disease (SD). The drug was well-tolerated with no dose-limiting toxicity (DLT) observed.-Fineline Info & Tech